From: Malaria treatment policy change in Uganda: what role did evidence play?
 | Donors | MoH | NMS | NDA | Service providers | CSO | Pharmaceutical company | Media | Researchers | Total |
---|---|---|---|---|---|---|---|---|---|---|
Characteristics of available evidence | 10 | 20 | 2 | Â | 14 | 4 | 4 | Â | 3 | 57 |
MoH institutional capacity to lead the KT process | 1 | 8 | Â | 2 | 2 | 3 | Â | Â | 4 | 20 |
Partnerships for KT | 3 | 7 | Â | 1 | 3 | 2 | 1 | Â | 1 | 18 |
Availability of tools and inputs to implement evidence | 2 | 5 | Â | Â | 9 | 1 | Â | Â | Â | 17 |
WHO intervention | 3 | 4 | Â | Â | Â | 1 | Â | Â | 1 | 9 |